339 related articles for article (PubMed ID: 27981444)
1. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
Shah RR
Drug Saf; 2017 Mar; 40(3):211-228. PubMed ID: 27981444
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
[TBL] [Abstract][Full Text] [Related]
3. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Geuna E; Roda D; Rafii S; Jimenez B; Capelan M; Rihawi K; Montemurro F; Yap TA; Kaye SB; De Bono JS; Molife LR; Banerji U
Br J Cancer; 2015 Dec; 113(11):1541-7. PubMed ID: 26554652
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets of metformin antitumor action.
Sośnicki S; Kapral M; Węglarz L
Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Gong J; Kelekar G; Shen J; Shen J; Kaur S; Mita M
Target Oncol; 2016 Aug; 11(4):447-67. PubMed ID: 26864078
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
8. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
9. Metformin in cancer.
Mallik R; Chowdhury TA
Diabetes Res Clin Pract; 2018 Sep; 143():409-419. PubMed ID: 29807101
[TBL] [Abstract][Full Text] [Related]
10. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
[TBL] [Abstract][Full Text] [Related]
13. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
14. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
15. Metformin targets multiple signaling pathways in cancer.
Lei Y; Yi Y; Liu Y; Liu X; Keller ET; Qian CN; Zhang J; Lu Y
Chin J Cancer; 2017 Jan; 36(1):17. PubMed ID: 28126011
[TBL] [Abstract][Full Text] [Related]
16. A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
Zhou JY; Xu B; Li L
Drug Dev Res; 2015 Sep; 76(6):263-9. PubMed ID: 26936407
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
[TBL] [Abstract][Full Text] [Related]
18. Metformin: a therapeutic opportunity in breast cancer.
Gonzalez-Angulo AM; Meric-Bernstam F
Clin Cancer Res; 2010 Mar; 16(6):1695-700. PubMed ID: 20215559
[TBL] [Abstract][Full Text] [Related]
19. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M
Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410
[TBL] [Abstract][Full Text] [Related]
20. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
